Moderna mRNA vaccine almost halves the risk of skin cancer returning
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts the risk of death or melanoma recurrence by 42 percent in late-stage trial results. The long-awaited data for treatment-resistant melanoma prompted an early release after a data leak ahead of an official presentation. While oncologists praised the positive findings as a major advancement, Moderna shares plunged following the leak as investors digested the trial details. More research is required to speed up personalized therapies and target other tumors.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna and Merck reported that their personalized mRNA cancer vaccine cut death and recurrence by 42 percent.
- ✓ The late-stage trial evaluated patients with treatment-resistant melanoma.
- ✓ Moderna shares plunged following the premature leak of the cancer vaccine data.
What changed
Moderna and Merck published phase 3 trial data early after a premature data leak.
Live updates
-
Moderna mRNA Cancer Vaccine Cuts Melanoma Relapse Risk
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts the risk of death or melanoma recurrence by 42 percent in late-stage trial results. The long-awaited data for treatment-resistant melanoma prompted an early release after a data leak ahead of an official presentation. While oncologists praised the positive findings as a major advancement, Moderna shares plunged following the leak as investors digested the trial details. More research is required to speed up personalized therapies and target other tumors.
Why it matters
The late-stage trial evaluation centers on treatment-resistant melanoma, representing a major milestone for messenger RNA technology applied beyond infectious diseases. The early disclosure occurred after data leaked prematurely ahead of an expected medical society presentation, triggering sharp stock market volatility for Moderna. Medical professionals have hailed the vaccine approach as a breakthrough for oncology.
What is confirmed
- Moderna and Merck reported that their personalized mRNA cancer vaccine cut death and recurrence by 42 percent.
- The late-stage trial evaluated patients with treatment-resistant melanoma.
- Moderna shares plunged following the premature leak of the cancer vaccine data.
What to watch next
- Full peer-reviewed publication of the phase 3 melanoma trial data.
- Upcoming presentations at medical society meetings such as ESMO.
- Regulatory steps and timelines for bringing personalized cancer vaccines to the clinic.
confidence 100%Sources used for this update (28)
- preview-www.nature.com — News in 2026 | Nature
- www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
- CNBC — Moderna shares plunge after leak of cancer vaccine data despite positive results
- Ars Technica — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- The Washington Post — Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
- Fierce Biotech — After leak, Merck and Moderna post phase 3 cancer vaccine data early
- The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
- Bloomberg.com — Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares
- CNBC — Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
- NBC News — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
- Nature — Moderna mRNA vaccine almost halves the risk of skin cancer returning
- Yahoo Finance — Moderna stock extends losses as investors digest melanoma vaccine trial data
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community